CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ANCA-associated Vasculitis
Conditions
ANCA-associated Vasculitis
Trial Timeline
Feb 4, 2015 → Jul 19, 2016
NCT ID
NCT02222155About CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids
CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids is a phase 2 stage product being developed by Amgen for ANCA-associated Vasculitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02222155. Target conditions include ANCA-associated Vasculitis.
What happened to similar drugs?
0 of 2 similar drugs in ANCA-associated Vasculitis were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02222155 | Phase 2 | Completed |
Competing Products
3 competing products in ANCA-associated Vasculitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| rituximab + Placebo | Roche | Phase 3 | 40 |
| Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine | Amgen | Phase 3 | 40 |
| Abatacept (Orencia) | Bristol Myers Squibb | Phase 2 | 27 |